Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study
Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy. In this open-label, single-arm study, patients (n = 255) with solid tu...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2007, Vol.59 (1), p.35-42 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 42 |
|---|---|
| container_issue | 1 |
| container_start_page | 35 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 59 |
| creator | DE CASTRO, Javier ORDONEZ, Amalio ISIA, Dolores SANCHEZ, Alfredo ARRIVI, Antonio MANZANO, José Luis GONZALEZ BARON, Manuel |
| description | Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy.
In this open-label, single-arm study, patients (n = 255) with solid tumours and haemoglobin (Hb) levels 1 g/dl of baseline within 4 weeks of treatment initiation. Mean Hb levels had improved from 10.8 +/- 1.0 g/dl at baseline to 12.2 +/- 1.8 g/dl by the final visit. Quality of life measured by linear analogue scale assessment significantly (P < 0.01) improved in patients achieving a Hb response (n = 159).
Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy. |
| doi_str_mv | 10.1007/s00280-006-0251-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_213423181</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1192403641</sourcerecordid><originalsourceid>FETCH-LOGICAL-c356t-282bba6d76815a8515b55a57f4b20778e50b92c0e717f7543ee97678426974743</originalsourceid><addsrcrecordid>eNpFkc1q3TAQRkVpaW7SPkA3RRSyVDP6s-TuSkibQiCbdm1ke9yrYMuuJCfc5-mLRjfXkNWA5nzfIA4hnzh85QDmKgEICwygYiA0Z-oN2XElBQOr5FuyA6kU0wbUGTlP6QEAFJfyPTnjlTVK1XZH_t-4OB6oDxnjI4bs50CffN5TXGbMPtAWs6NLxOMy0VRmROqCw8m7EqOLy_5l9ZJK8-h7mtdpXmOiETv0jz78pctYsLBOrHUJe9rtcZrzHqNbDvRb4dI6lop5oOWRBpy3gzTltT98IO8GNyb8uM0L8ufHze_rW3Z3__PX9fc71kldZSasaFtX9aayXDuruW61dtoMqhVgjEUNbS06QMPNYLSSiLWpjFWiqo0ySl6QL6feJc7_Vky5eSjfCOVkI7hUQnLLC8RPUBfnlCIOzRL95OKh4dAcrTQnK02x0hytNMfiz1vx2k7YvyY2DQW43ACXOjcO0YXOp1fOKqi1NPIZ8TOX0Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213423181</pqid></control><display><type>article</type><title>Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>DE CASTRO, Javier ; ORDONEZ, Amalio ; ISIA, Dolores ; SANCHEZ, Alfredo ; ARRIVI, Antonio ; MANZANO, José Luis ; GONZALEZ BARON, Manuel</creator><creatorcontrib>DE CASTRO, Javier ; ORDONEZ, Amalio ; ISIA, Dolores ; SANCHEZ, Alfredo ; ARRIVI, Antonio ; MANZANO, José Luis ; GONZALEZ BARON, Manuel</creatorcontrib><description>Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy.
In this open-label, single-arm study, patients (n = 255) with solid tumours and haemoglobin (Hb) levels </= 13 g/dl (men) or </= 12 g/dl (women) received epoetin beta 450 IU/kg ( approximately 30,000 IU) weekly until 4 weeks after their last platinum-based chemotherapy cycle.
An anaemia prevention response [defined as patients with a Hb response (increase in Hb level > 1 g/dl from baseline) plus patients whose Hb levels remained +/- 1 g/dl of baseline throughout the study] was observed in 234 patients (92%). Response to epoetin beta was rapid. Of the 159 patients achieving a Hb response, 139 (87%) had Hb levels > 1 g/dl of baseline within 4 weeks of treatment initiation. Mean Hb levels had improved from 10.8 +/- 1.0 g/dl at baseline to 12.2 +/- 1.8 g/dl by the final visit. Quality of life measured by linear analogue scale assessment significantly (P < 0.01) improved in patients achieving a Hb response (n = 159).
Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-006-0251-4</identifier><identifier>PMID: 16874498</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Activities of Daily Living ; Adult ; Aged ; Aged, 80 and over ; Anemia - chemically induced ; Anemia - prevention & control ; Anemia - psychology ; Anemias. Hemoglobinopathies ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Diseases of red blood cells ; Erythropoietin - adverse effects ; Erythropoietin - therapeutic use ; Female ; Ferritins - metabolism ; Hematologic and hematopoietic diseases ; Hemoglobins - metabolism ; Humans ; Iron - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Multiple tumors. Solid tumors. Tumors in childhood (general aspects) ; Neoplasms - complications ; Neoplasms - drug therapy ; Neoplasms - psychology ; Organoplatinum Compounds - adverse effects ; Organoplatinum Compounds - therapeutic use ; Pharmacology. Drug treatments ; Quality of Life ; Recombinant Proteins ; Tumors</subject><ispartof>Cancer chemotherapy and pharmacology, 2007, Vol.59 (1), p.35-42</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c356t-282bba6d76815a8515b55a57f4b20778e50b92c0e717f7543ee97678426974743</citedby><cites>FETCH-LOGICAL-c356t-282bba6d76815a8515b55a57f4b20778e50b92c0e717f7543ee97678426974743</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18409537$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16874498$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DE CASTRO, Javier</creatorcontrib><creatorcontrib>ORDONEZ, Amalio</creatorcontrib><creatorcontrib>ISIA, Dolores</creatorcontrib><creatorcontrib>SANCHEZ, Alfredo</creatorcontrib><creatorcontrib>ARRIVI, Antonio</creatorcontrib><creatorcontrib>MANZANO, José Luis</creatorcontrib><creatorcontrib>GONZALEZ BARON, Manuel</creatorcontrib><title>Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy.
In this open-label, single-arm study, patients (n = 255) with solid tumours and haemoglobin (Hb) levels </= 13 g/dl (men) or </= 12 g/dl (women) received epoetin beta 450 IU/kg ( approximately 30,000 IU) weekly until 4 weeks after their last platinum-based chemotherapy cycle.
An anaemia prevention response [defined as patients with a Hb response (increase in Hb level > 1 g/dl from baseline) plus patients whose Hb levels remained +/- 1 g/dl of baseline throughout the study] was observed in 234 patients (92%). Response to epoetin beta was rapid. Of the 159 patients achieving a Hb response, 139 (87%) had Hb levels > 1 g/dl of baseline within 4 weeks of treatment initiation. Mean Hb levels had improved from 10.8 +/- 1.0 g/dl at baseline to 12.2 +/- 1.8 g/dl by the final visit. Quality of life measured by linear analogue scale assessment significantly (P < 0.01) improved in patients achieving a Hb response (n = 159).
Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy.</description><subject>Activities of Daily Living</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anemia - chemically induced</subject><subject>Anemia - prevention & control</subject><subject>Anemia - psychology</subject><subject>Anemias. Hemoglobinopathies</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Diseases of red blood cells</subject><subject>Erythropoietin - adverse effects</subject><subject>Erythropoietin - therapeutic use</subject><subject>Female</subject><subject>Ferritins - metabolism</subject><subject>Hematologic and hematopoietic diseases</subject><subject>Hemoglobins - metabolism</subject><subject>Humans</subject><subject>Iron - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</subject><subject>Neoplasms - complications</subject><subject>Neoplasms - drug therapy</subject><subject>Neoplasms - psychology</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Organoplatinum Compounds - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Quality of Life</subject><subject>Recombinant Proteins</subject><subject>Tumors</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNpFkc1q3TAQRkVpaW7SPkA3RRSyVDP6s-TuSkibQiCbdm1ke9yrYMuuJCfc5-mLRjfXkNWA5nzfIA4hnzh85QDmKgEICwygYiA0Z-oN2XElBQOr5FuyA6kU0wbUGTlP6QEAFJfyPTnjlTVK1XZH_t-4OB6oDxnjI4bs50CffN5TXGbMPtAWs6NLxOMy0VRmROqCw8m7EqOLy_5l9ZJK8-h7mtdpXmOiETv0jz78pctYsLBOrHUJe9rtcZrzHqNbDvRb4dI6lop5oOWRBpy3gzTltT98IO8GNyb8uM0L8ufHze_rW3Z3__PX9fc71kldZSasaFtX9aayXDuruW61dtoMqhVgjEUNbS06QMPNYLSSiLWpjFWiqo0ySl6QL6feJc7_Vky5eSjfCOVkI7hUQnLLC8RPUBfnlCIOzRL95OKh4dAcrTQnK02x0hytNMfiz1vx2k7YvyY2DQW43ACXOjcO0YXOp1fOKqi1NPIZ8TOX0Q</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>DE CASTRO, Javier</creator><creator>ORDONEZ, Amalio</creator><creator>ISIA, Dolores</creator><creator>SANCHEZ, Alfredo</creator><creator>ARRIVI, Antonio</creator><creator>MANZANO, José Luis</creator><creator>GONZALEZ BARON, Manuel</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope></search><sort><creationdate>2007</creationdate><title>Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study</title><author>DE CASTRO, Javier ; ORDONEZ, Amalio ; ISIA, Dolores ; SANCHEZ, Alfredo ; ARRIVI, Antonio ; MANZANO, José Luis ; GONZALEZ BARON, Manuel</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c356t-282bba6d76815a8515b55a57f4b20778e50b92c0e717f7543ee97678426974743</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Activities of Daily Living</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anemia - chemically induced</topic><topic>Anemia - prevention & control</topic><topic>Anemia - psychology</topic><topic>Anemias. Hemoglobinopathies</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Diseases of red blood cells</topic><topic>Erythropoietin - adverse effects</topic><topic>Erythropoietin - therapeutic use</topic><topic>Female</topic><topic>Ferritins - metabolism</topic><topic>Hematologic and hematopoietic diseases</topic><topic>Hemoglobins - metabolism</topic><topic>Humans</topic><topic>Iron - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Multiple tumors. Solid tumors. Tumors in childhood (general aspects)</topic><topic>Neoplasms - complications</topic><topic>Neoplasms - drug therapy</topic><topic>Neoplasms - psychology</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Organoplatinum Compounds - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Quality of Life</topic><topic>Recombinant Proteins</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DE CASTRO, Javier</creatorcontrib><creatorcontrib>ORDONEZ, Amalio</creatorcontrib><creatorcontrib>ISIA, Dolores</creatorcontrib><creatorcontrib>SANCHEZ, Alfredo</creatorcontrib><creatorcontrib>ARRIVI, Antonio</creatorcontrib><creatorcontrib>MANZANO, José Luis</creatorcontrib><creatorcontrib>GONZALEZ BARON, Manuel</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DE CASTRO, Javier</au><au>ORDONEZ, Amalio</au><au>ISIA, Dolores</au><au>SANCHEZ, Alfredo</au><au>ARRIVI, Antonio</au><au>MANZANO, José Luis</au><au>GONZALEZ BARON, Manuel</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2007</date><risdate>2007</risdate><volume>59</volume><issue>1</issue><spage>35</spage><epage>42</epage><pages>35-42</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Anaemia is common during platinum-based chemotherapy. This study aimed to evaluate the efficacy and safety of epoetin beta in the prevention of severe anaemia in patients with solid tumours receiving concomitant platinum therapy.
In this open-label, single-arm study, patients (n = 255) with solid tumours and haemoglobin (Hb) levels </= 13 g/dl (men) or </= 12 g/dl (women) received epoetin beta 450 IU/kg ( approximately 30,000 IU) weekly until 4 weeks after their last platinum-based chemotherapy cycle.
An anaemia prevention response [defined as patients with a Hb response (increase in Hb level > 1 g/dl from baseline) plus patients whose Hb levels remained +/- 1 g/dl of baseline throughout the study] was observed in 234 patients (92%). Response to epoetin beta was rapid. Of the 159 patients achieving a Hb response, 139 (87%) had Hb levels > 1 g/dl of baseline within 4 weeks of treatment initiation. Mean Hb levels had improved from 10.8 +/- 1.0 g/dl at baseline to 12.2 +/- 1.8 g/dl by the final visit. Quality of life measured by linear analogue scale assessment significantly (P < 0.01) improved in patients achieving a Hb response (n = 159).
Epoetin beta effectively prevents anaemia in most patients with solid tumours receiving concurrent platinum-based chemotherapy.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>16874498</pmid><doi>10.1007/s00280-006-0251-4</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2007, Vol.59 (1), p.35-42 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_213423181 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Activities of Daily Living Adult Aged Aged, 80 and over Anemia - chemically induced Anemia - prevention & control Anemia - psychology Anemias. Hemoglobinopathies Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Biological and medical sciences Diseases of red blood cells Erythropoietin - adverse effects Erythropoietin - therapeutic use Female Ferritins - metabolism Hematologic and hematopoietic diseases Hemoglobins - metabolism Humans Iron - therapeutic use Male Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasms - complications Neoplasms - drug therapy Neoplasms - psychology Organoplatinum Compounds - adverse effects Organoplatinum Compounds - therapeutic use Pharmacology. Drug treatments Quality of Life Recombinant Proteins Tumors |
| title | Early intervention with epoetin beta prevents severe anaemia in patients with solid tumours receiving platinum-based chemotherapy : results of the neoprevent study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T21%3A47%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Early%20intervention%20with%20epoetin%20beta%20prevents%20severe%20anaemia%20in%20patients%20with%20solid%20tumours%20receiving%20platinum-based%20chemotherapy%20:%20results%20of%20the%20neoprevent%20study&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=DE%20CASTRO,%20Javier&rft.date=2007&rft.volume=59&rft.issue=1&rft.spage=35&rft.epage=42&rft.pages=35-42&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-006-0251-4&rft_dat=%3Cproquest_cross%3E1192403641%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=213423181&rft_id=info:pmid/16874498&rfr_iscdi=true |